SAN DIEGO—Treatment of type 2 diabetes with metformin alone or in combination with other hypoglycemic agents is associated with decreased all-cause mortality compared with anti-diabetic regimens that do not contain metformin, data suggest.
The findings, presented here at Renal Week 2006, are based on a study of 1,306 type 2 diabetics receiving treatment at the Veterans Affairs Medical Center in Memphis, Tenn. Of these patients, 1,207 were metformin users and 999 were not. Metformin users had a 23% lower risk of all-cause mortality than non-metformin users after adjusting for potential confounders. Additionally, patients exposed to insulin had increased mortality even after adjusting for differences in baseline characteristics, the investigators found.
Continue Reading
